• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of January 6

Article

The Center for Biosimilars® recaps the top stories for the week of January 6.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 6, 2019.

Number 5: A recent study finds that peer influence factors heavily into whether oncologists decide to adopt bevacizumab for their patients.

Number 4: The FDA notes the approval of 10 biosimilars in its 2019 report of drug approvals, which included 48 novel drugs.

Number 3: A look back at the top 5 legal stories in 2019 finds that cases involving adalimumab featured in 2 of them.

Number 2: Novo Nordisk takes 3 steps to improve insulin affordability, and says the FDA expanded use of its fast-acting mealtime insulin to children as young as 2.

Number 1: Pfizer says it is launching its bevacizumab biosimilar, Zirabev, in the United States.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Lakesha Farmer, PharmD
Lakesha Farmer from Cencora
Ha Kung Wong, JD
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
 Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health.
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.